Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (31-40 of 162) with videos related to

Pageof 17
Sort By:
Thrombosis and Haemostasis|May 6, 2006
Quantitation of Vervet monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and plateletsLester M Meissenheimer, Koen Verbeke, Paul J Declerck, et al.
Biophysical Journal|January 18, 2005
The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent eventChristian Boudier, Ann Gils, Paul J Declerck, et al.
Thrombosis and Haemostasis|January 24, 2003
Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivativeKoen Verbeke, Ann Gils, Jean-Marie Stassen, et al.
Thrombosis and Haemostasis|September 1, 2009
Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)Ann Gils, Lester M Meissenheimer, Griet Compernolle, et al.
Therapeutic Advances in Gastroenterology|February 1, 2018
Immunogenicity of biologics in inflammatory bowel diseaseSéverine Vermeire, Ann Gils, Paola Accossato, et al.
Thrombosis Research|April 22, 2014
Clot stability and fibrin deposition is strongly reduced in mice in which mouse TAFI is replaced by human TAFINiraj Mishra, Joost C M Meijers, Paul J Declerck, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 19, 2019
Anti-infliximab antibodies: How to compare old and new data?Maya Imbrechts, Thomas Van Stappen, Griet Compernolle, et al.
Biophysical Journal|June 28, 2003
Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1Stefan Verheyden, Alain Sillen, Ann Gils, et al.
Clinical Pharmacology : Advances and Applications|October 19, 2017
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseasesErwin Dreesen, Peter Bossuyt, Denis Mulleman, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 8, 2005
Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysisKatarzyna Smolarczyk, Joanna Boncela, Jacek Szymanski, et al.
Pageof 17

Showing results (31-40 of 162) with videos related to

Sort By:
Pageof 17
Thrombosis and Haemostasis|May 6, 2006
Quantitation of Vervet monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and plateletsLester M Meissenheimer, Koen Verbeke, Paul J Declerck, et al.
Biophysical Journal|January 18, 2005
The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent eventChristian Boudier, Ann Gils, Paul J Declerck, et al.
Thrombosis and Haemostasis|January 24, 2003
Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivativeKoen Verbeke, Ann Gils, Jean-Marie Stassen, et al.
Thrombosis and Haemostasis|September 1, 2009
Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)Ann Gils, Lester M Meissenheimer, Griet Compernolle, et al.
Therapeutic Advances in Gastroenterology|February 1, 2018
Immunogenicity of biologics in inflammatory bowel diseaseSéverine Vermeire, Ann Gils, Paola Accossato, et al.
Thrombosis Research|April 22, 2014
Clot stability and fibrin deposition is strongly reduced in mice in which mouse TAFI is replaced by human TAFINiraj Mishra, Joost C M Meijers, Paul J Declerck, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 19, 2019
Anti-infliximab antibodies: How to compare old and new data?Maya Imbrechts, Thomas Van Stappen, Griet Compernolle, et al.
Biophysical Journal|June 28, 2003
Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1Stefan Verheyden, Alain Sillen, Ann Gils, et al.
Clinical Pharmacology : Advances and Applications|October 19, 2017
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseasesErwin Dreesen, Peter Bossuyt, Denis Mulleman, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 8, 2005
Fibrinogen contains cryptic PAI-1 binding sites that are exposed on binding to solid surfaces or limited proteolysisKatarzyna Smolarczyk, Joanna Boncela, Jacek Szymanski, et al.
Pageof 17